Independent Financial Group LLC Buys New Position in Danaher Corporation $DHR

Independent Financial Group LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,790 shares of the conglomerate’s stock, valued at approximately $719,000.

A number of other hedge funds have also added to or reduced their stakes in DHR. Norges Bank acquired a new stake in shares of Danaher during the 4th quarter worth approximately $2,177,106,000. Viking Global Investors LP lifted its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Danaher by 104.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock worth $991,923,000 after acquiring an additional 2,216,789 shares in the last quarter. Wellington Management Group LLP grew its holdings in Danaher by 11.2% in the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after purchasing an additional 1,517,904 shares during the period. Finally, Capital International Investors grew its holdings in Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher posted Q2 adjusted EPS of $1.94, above the $1.84 consensus, and revenue of about $6.26 billion to $6.3 billion, also ahead of estimates. Danaher Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year adjusted EPS guidance, showing confidence in profitability despite the softer sales backdrop. Danaher Corp (DHR) Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Life Sciences was a bright spot, with stronger sales growth, but bioprocessing revenue came in weaker than expected and was cited as a drag on sentiment. Reuters: Danaher’s revenue outlook cut, biotech miss overshadow profit forecast raise
• Negative Sentiment: Investors reacted negatively to the reduced core revenue growth outlook and cautious near-term guidance, which outweighed the earnings beat and led to the stock decline. Danaher stock slips despite Q2 earnings beat, raised guidance
• Negative Sentiment: Analysts also highlighted “surprisingly soft” bioprocessing sales, reinforcing concerns that growth may slow more than expected. Danaher Plummets After One Segment Comes In ‘Surprisingly Soft’

Danaher Price Performance

Shares of NYSE:DHR opened at $179.01 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. The stock has a market cap of $126.70 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 2.48 and a beta of 0.79. The stock’s fifty day simple moving average is $184.22 and its two-hundred day simple moving average is $197.69. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.10. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.11 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 EPS. As a group, analysts forecast that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio is presently 30.95%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DHR. Morgan Stanley dropped their price objective on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Jefferies Financial Group restated a “buy” rating and issued a $245.00 target price on shares of Danaher in a research note on Tuesday, April 21st. Wells Fargo & Company decreased their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 22nd. Robert W. Baird dropped their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. reduced their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $231.64.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.